

Form PTO 1449		
ATTY DOCKET NO. 33-02	SERIAL NO. 10/687,558	FILING DATE October 15, 2003
APPLICANT Kwon et al.		GROUP 1614

**U.S. PATENT DOCUMENTS**















Exmr Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
W	6,322,810	11/27/01	Alkan-Onyuksel	424	450	
	6,020,121	02/01/00	Bao et al.	435	4	
	6,013,283	1/11/00	Greenwald et al.	424	486	
	5,686,110	11/11/97	Greenwald et al.	424	486	
	5,059,591	10/22/91	Janoff et al.	514	31	
	5,929,177	7/27/99	Kataoka et al.	525	408	
	5,925,720	7/20/99	Kataoka et al.	525	523	
	6,413,537	7/2/02	Kwon et al.	424	423	
	6,217,886	4/17/01	Önyüksel et al.	424	401	
	5,510,103	4/23/96	Yokoyama et al.	424	78.08	
W	5,449,513	9/12/95	Yokoyama et al.	424	78.08	

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation Yes/No
W	85/05030	21/11/85	WO	A61K	9/40	No
	03/037295	8/5/03	WO	A61K	9/00	No
	03/002096	9/1/03	WO	A61K	9/127	No
W	0 166 596 A2	24/06/95	EP	A 61K	9/22	No

Form PTO 1449		
ATTY DOCKET NO. 33-02	SERIAL NO. 10/687,558	FILING DATE October 15, 2003
APPLICANT Kwon et al.		GROUP 1614

## OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, etc.)

		Adams, ML et . (2002) "The effects of acyl chain length on the micelle properties of poly(ethylene oxide)-block-poly(N-hexyl-L-aspartamide)-acyl conjugates"; <i>J. Biomat. Sci., Polym. Ed.</i> 13(9):991-1006.
		Allen, C et al. (1999) "Nano-Engineering Block Copolymer Aggregates for Drug Delivery"; <i>Colloids &amp; Surfaces B: Biointerfaces</i> 16:3-27.
		Andes, D et al. (Mar.2001) "Pharmacodynamics of Amphotericin B in a Neutropenic-Mouse Disseminated-Candidiasis Model"; <i>Antimicrob. Agents Chemother.</i> 45:922-926.
		Andes, D et al. (1999) "Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model"; <i>Antimicrob. Agents Chemother.</i> 43:2116-2120.
		Barwicz, J et al. (1992) "Effects of the Aggregation State of Amphotericin B on Its Toxicity to Mice"; <i>Antimicrob. Agents Chemother.</i> 36:2310-2315.
		Bolard , J. et al. (1991) "One-Sided Action of Amphotericin B on Cholesterol-Containing Membranes Is Determined by Its Self-Association in the Medium"; <i>Biochemistry</i> 30:5707-5715.
		Brajtburg, J et al. (1996) "Carrier Effects on Biological Activity of Amphotericin B"; <i>Clin. Microbiol. Rev.</i> 9(4):512-531.
		Espuelas, MS et al. (1998) "Interaction of Amphotericin B with Polymeric Colloids. A spectroscopic Study"; <i>Colloids and Surfaces BN: Biointerfaces</i> 11:141-151.
		Forster, D et al. (1988) "Toxicity of Solubilized and Colloidal Amphotericin B Formulations to Human Erythrocytes"; <i>Journal Pharm. Pharmacol.</i> 40:325-328.
		Gruda, I et al. (1988) "Effect of the aggregation state of amphotericin B on its interaction with ergosterol"; <i>Biochem. Cell Biol.</i> 66:177-183.
		Jones, MC et al. (1999) "Polymeric micelles - a new generation of colloidal drug carriers"; <i>Eur. J. Pharm. Biopharm.</i> 48:101-111.
		Kataoka, K et al (Feb.2000) "Doxorubicin-Loaded Poly(ethylene glycol)-Poly( $\beta$ -benzyl-L-aspartate) Copolymer Micelles: Their Pharmaceutical Characteristics and Biological Significance"; <i>J. Controlled Release</i> 64:143-153.
		Kataoka, K et al (1993) "Block Copolymer Micelles as Vehicles for Drug Delivery"; <i>J. Controlled Release</i> 24:119-132.
		Kwon, GS et al. (1999) "Soluble Self-Assembled Block Copolymers for Drug Delivery" <i>Pharm. Res.</i> 16(5):597-600.

Form PTO 1449		
ATTY DOCKET NO. 33-02	SERIAL NO. 10/687,558	FILING DATE October 15, 2003
APPLICANT Kwon et al.		GROUP 1614

hu		Kwon, GS et al. (1998) "Diblock Copolymer Nanoparticles for Drug Delivery"; <i>Crit. Ther. Drug. Carrier Syst.</i> 15(5):481-512.
		Kwon, GS (Feb. 1995) "Physical entrapment of adriamycin in AB block copolymer micelles"; <i>Pharm. Res.</i> 12(2):192-195.
		Kwon, GS et al. (July 1993) "Biodistribution of micelle-forming polymer-drug conjugates"; <i>Pharm. Res.</i> 10(7):970-974.
		Kwon, GS (1993) "Micelles Based on AB Block Copolymers of Poly(ethylene oxide) and Poly( $\beta$ -benzyl L-aspartate)"; <i>Langmuir</i> 9:945-949.
		Kwon, G et al. (1994) "Block Copolymer Micelles as Vehicles for Hydrophobic Drugs"; <i>Colloids &amp; Surfaces B: Biointerfaces</i> 2:429-434.
		Kwon, G et al. (2003) "Polymeric micelles for the delivery of polyene antibiotics"; <i>Polymeric Materials: Science &amp; Engineering</i> 89:50.
		Lavasanifar, A et al. (April 2002) "Block Copolymer Micelles for the Encapsulation and Delivery of Amphotericin B" <i>Pharm. Res.</i> 19(4):418-422.
		Lavasanifar, A et al. (Feb. 2002) "The Effect of Fatty Acid Substitution on the <i>In Vitro</i> Release of Amphotericin B from Micelles Composed of Poly(ethylene oxide)-Block-poly( <i>N</i> -hexyl stearate-L-aspartamide)"; <i>Journal of Controlled Release</i> 79:165-172.
		Lavasanifar, A et al. (Oct. 2001) "The effect of alkyl core structure on micellar properties of poly(ethylene oxide)-block-poly(L-aspartamide) derivatives"; <i>Colloids and Surfaces B: Biointerfaces</i> 22(2):115-126.
		Lavasanifar, A et al. (Nov. 2001) "Micelles Self-Assembled from poly(ethylene oxide)-Block-poly( <i>N</i> -hexyl stearate-L-aspartamide) by a Solvent Evaporation Method: Effect on the Solubilization and Haemolytic Activity of Amphotericin B"; <i>Journal of Controlled Release</i> 77:155-160.
		Lavasanifar, A et al. (Dec. 2000) "Micelles of poly(ethylene oxide)-block-poly( <i>N</i> -alkyl stearate L-aspartamide): Synthetic Analogues of Lipoproteins for Drug Delivery"; <i>Journal Biomed. Mater. Res.</i> 52:831-835.
		Lavasanifar, A et al. (1999) "Artificial Lipoproteins for the Delivery of Amphotericin B"; <i>Proc. Int. Symp. Controlled Release Bioact. Mater.</i> 26:647-648.
hu		Li, Y et al. (2000), "Methotrexate Esters of Poly(ethylene oxide)-Block-Poly(2-hydroxyethyl-L-aspartamide). Part I: Effects of the Level of Methotrexate Conjugation on the Stability of Micelles and on Drug Release"; <i>Pharm. Res.</i> 17(5):607-611.

Form PTO 1449		
ATTY DOCKET NO. 33-02	SERIAL NO. 10/687,558	FILING DATE October 15, 2003
APPLICANT Kwon et al.		GROUP 1614

W			Li, Y et al. (1999) "Micelle-like Structures of poly(ethylene oxide)-block-poly(2-hydroxyethyl aspartamide)-methotrexate Conjugates"; <i>Colloids &amp; Surfaces B: Biointerfaces</i> 16:217-226.
			Moribe and Maruyama (2002) "Pharmaceutical Design of the Liposomal Antimicrobial Agents for Infectious Disease"; <i>Current Pharm. Design</i> 8:441-454.
			Moribe, K et al. (1999) "Molecular localization and state of amphotericin B in PEG liposomes"; <i>Internat. J. Pharmaceutics</i> 193(1):97-106.
			Moribe, K et al. (1999) "Encapsulation characteristics of nystatin in liposomes: effects of cholesterol and polyethylene glycol derivatives"; <i>Internat. J. Pharmaceutics</i> 188:193-202.
			Moribe, K et al. (1998) "Enhanced Encapsulation of Amphotericin B into Liposomes by Complex Formation with Polyethylene Glycol Derivatives"; <i>Pharmaceutical Res.</i> 15:1737-1742.
			Nagarajan, R et al. (1986) "Unusual Selectivity in Solubilization by Block Copolymer Micelles" <i>Langmuir</i> 2:210-215.
			Nakanishi, T et al. (July 2001) "Development of the Polymer Micelle Carrier System for Doxorubicin" <i>J. Controlled Release</i> 74:295-302.
			Newman, KD et al. (June 25 2000) "Cytoplasmic delivery of a macromolecular fluorescent probe by poly(d,l-lactic-co-glycolic acid) microspheres"; <i>J. Biomed. Mater. Res.</i> 50(4):591-597.
			Otsubo, T et al. (1998) "Long-Circulating Immunoliposomal Amphotericin B Against Invasive Pulmonary Aspergillosis in Mice"; <i>Antimicrob. Agents Chemother.</i> 42(1):40-44.
			Tasset, C et al. (1991) "The Influence of Myrj 59 on the Solubility, Toxicity and Activity of Amphotericin B"; <i>J. Pharm. Pharmacol.</i> 43:297-302.
			Tasset, C et al. (1990) "Effect of polyoxyethyleneglycol (24) cholesterol on the solubility, toxicity and activity of amphotericin B"; <i>Int. J. of Pharmaceutics</i> 58:41-48.
			Torchilin, VP et al. (2001) "Structure and design of polymeric surfactant-based drug delivery systems"; <i>J. Controlled Release</i> 73:137-172.
			Van Eten, EWM (Mar.2000) "Efficacy of Liposomal Amphotericin B with Prolonged Circulation in Blood in Treatment of Severe Pulmonary Aspergillosis in Leukopenic Rats"; <i>Antimicrob. Agents Chemother.</i> 44(3):540-545.
W			Van Eten, EWM et al. (1998). "Superior Efficacy of Liposomal Amphotericin B with Prolonged Circulation in Blood in the Treatment of Severe Candidiasis in Leukopenic Mice" <i>Antimicrob. Agents and Chemother.</i> 42(9):2431-2433.

Form PTO 1449		
ATTY DOCKET NO. 33-02	SERIAL NO. 10/687,558	FILING DATE October 15, 2003
APPLICANT Kwon et al.		GROUP 1614

lu		Van Etten, EWM et al (1998) "Activity of Liposomal Amphotericin B with Prolonged Circulation in Blood versus Those of AmBisome and Fungizone against Intracellular <i>Candida albicans</i> in Murine Peritoneal Macrophages"; <i>Antimicrob. Agents Chemother.</i> 42(9):2437-2439.
		Van Etten, EWM (1995) "Amphotericin B Liposomes with Prolonged Circulation in Blood: <i>In Vitro</i> Antifungal Activity, Toxicity, and Efficacy in Systemic Candidiasis in Leukopenic Mice"; <i>Antimicrob. Agents Chemother.</i> 39(9):1954-1958.
		Walsh, TJ et al. (1998) Safety, Tolerance, and Pharmacokinetics of a Small Unilamellar Liposomal Formulation of Amphotericin B (AmBisome) in Neutropenic Patients"; <i>Antimicrob. Agents Chemother.</i> 42(9):2391-2398.
		White, MH In "Progress in the use and delivery of polyenes in antifungal therapy"; <i>Antifungal Agents: discovery and mode of action</i> : BIOS Scientific Publishers Limited: Oxford, 1995, pp 69-75, Dixon, GK, Copping, LG, Hollomon, DW, Eds.
		Yamamoto, Y et al. (2002) "Temperature-related change in the properties relevant to drug delivery of poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles in aqueous milieu"; <i>J. Controlled Release.</i> 82:359-371.
		Yokoyama M et al. (1999) "Selective Delivery of Adriamycin to a Solid tumor Using a Polymeric Micelle Carrier System"; <i>J. Drug. Targeting</i> 7:171-186
		Yokoyama, M et al. (1998) "Incorporation of Water-Insoluble Anticancer Drug into Polymeric Micelles and Control of Their Particle Size"; <i>J. Controlled Release</i> 55:219-229.
		Yokoyama, M et al. (1998) "Characterization of Physical Entrapment and Chemical Conjugation of Adriamycin in Polymeric Micelles and Their Design for <i>In Vivo</i> Delivery of a Solid Tumor" <i>J. Controlled Release</i> 50:79-92.
		Yokoyama, M et al. (1992) "Preparation of Micelle-Forming Polymer-Drug Conjugates"; <i>Bioconjugate Chem.</i> 3:295-301.
		Yu, BG et al. (1998) " <i>In Vitro</i> Dissociation of Antifungal Efficacy and Toxicity for Amphotericin B-Loaded Poly(Ethylene Oxide)-Block-Poly( $\beta$ -benzyl-L-aspartate) Micelles"; <i>J. Controlled Release</i> 56:285-291.
		Yu, BG et al. (1998) "Polymeric Micelles for Drug Delivery: Solubilization and Haemolytic Activity of Amphotericin B"; <i>J. Controlled Release</i> 53:131-136.
lu		

EXAMINER	ku	DATE CONSIDERED	1/21/07
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

Substitute for form 1449/PTO, based on PTO/SB/08A and 08B

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Application Number	10/687,558
Filing Date	October 15, 2003
First Named Inventor	Kwon
Art Unit	1614
Examiner Name	Page, Thurman K.
Attorney Docket Number	33-02

AUG 04 2004

**U.S. PATENT DOCUMENTS**

Examiner Initial*	Cite No. <sup>1</sup>	Document Number (US-)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)
<i>ku</i>		5,885,613	03/23/99	Holland et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No. <sup>1</sup>	Foreign Patent Document Number (include WIPO country code)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)	T <sup>2</sup>

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initial*	Cite No. <sup>1</sup>	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>

Examiner Signature	<i>ku</i>	Date Considered	1/21/07
--------------------	-----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional).

<sup>2</sup>Applicant is to place a check mark here or "x" if English language Translation is attached.